ANVS
Annovis Bio, Inc.3.9300
+0.1500+3.97%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
104.16MP/E (TTM)
-Basic EPS (TTM)
-1.43Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Annovis prices $6M offering
Annovis Bio priced a $6 million registered direct offering on October 10, 2025, selling 3.15 million common shares at $1.50 each and pre-funded warrants for 850,000 more, closing around October 14. Funds will fuel Phase 3 trials of Buntanetap for Alzheimer's while covering working capital. Directors and officers locked up shares for 45 days post-close. Yet dilution looms large.
8-K
Annovis names new CFO
Annovis Bio appointed Mark Guerin as CFO effective September 25, 2025, bringing his biopharma finance expertise from Onconova Therapeutics to steer the company through buntanetap's late-stage trials for Alzheimer's and Parkinson's. Guerin will earn a $450,000 base salary, 40% target bonus, and options for 200,000 shares, plus six months' severance. This hire bolsters financial oversight amid promising clinical progress. Forward-looking statements highlight risks in SEC filings.
8-K
CFO resigns; CEO takes interim role
Annovis Bio's VP of Finance Andrew Walsh resigned effective August 22, 2025, without any disagreements over operations or policies. CEO Maria Maccecchini steps in as Acting CFO starting August 15, while the board hunts for a permanent replacement. Leadership shuffle signals interim stability amid the biotech's ongoing trials. No financial impacts disclosed.
ANAB
AnaptysBio, Inc.
45.03-0.53
ANEB
Anebulo Pharmaceuticals, Inc.
2.23+0.02
ANNX
Annexon, Inc.
4.80-0.11
ANRO
Alto Neuroscience, Inc.
17.10+0.07
ANTX
AN2 Therapeutics, Inc.
1.16-0.01
AVXL
Anavex Life Sciences Corp.
4.02-0.12
BIVI
BioVie Inc.
1.43+0.00
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
NNNN
Anbio Biotechnology
28.01-0.39
NUVB
Nuvation Bio Inc.
8.66+0.15